- Molecular NameAmisulpride
- SynonymAminosultopride; amisulpride
- Weight369.486
- Drugbank_IDDB06288
- ACS_NO71675-85-9
- Show 2D model
- LogP (experiment)1.1
- LogP (predicted, AB/LogP v2.0)1.21
- pka9.37
- LogD (pH=7, predicted)-1.11
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-0.47
- LogSw (predicted, AB/LogsW2.0)0.86
- Sw (mg/ml) (predicted, ACD/Labs)0.88
- No.of HBond Donors3
- No.of HBond Acceptors7
- No.of Rotatable Bonds7
- TPSA110.11
- StatusFDA approved
- AdministrationOral, intramuscular
- PharmacologyA psychoactive drug that is used as an atypical antipsychotic and antidepressant.
- Absorption_valueN/A
- Absorption (description)Following oral administration of amisulpride, this drug is readily absorbed with two absorption peaks being observed, the first after about 1 h and the second between 3 and 4 h after administration.
- Caco_2N/A
- Bioavailability48.0
- Protein binding17.0
- Volume of distribution (VD)5.8 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmIt is only weakly metabolised; metabolites account for only about 4% of the dose and are inactive.
- Half life12 h
- ExcretionIt is excreted largely unchanged in urine (70%) and a small amount in faeces as the unchanged drug. Amisulpride is widely distributed throughout the body and is only very weakly dialysed.
- Urinary ExcretionN/A
- Clerance20 L/h
- ToxicityOverdoses of amisulpride have been linked with torsades de pointes.
- LD50 (rat)N/A
- LD50 (mouse)N/A